Sign inJoin waitlistJoin the waitlist

GA

Ghassan Abou-Alfa

Professor, Memorial Sloan Kettering Cancer Center · Univ of Maryland Sch of Med

Credentials: · · · · ·

History

Univ of Maryland Sch of Med
Present
Clinical Center at the National Institutes of Health
Present

Hematology and Medical Oncology
Yale-New Haven Hospital
1998–2000
Yale Univ Sch of Med
1992–1995
American Univ of Beirut, Beirut, Lebanon
1988–1992

Research

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
New England Journal of Medicine · 2018 · First of 22 authors · 1,916 citations
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
NEJM Evidence · 2022 · First of 31 authors · 1,418 citations
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
The Lancet Oncology · 2020 · First of 19 authors · Corresponding · 1,293 citations

EO
Eileen O'Reilly
100 papers
JH
James Harding
74 papers · 4 as a fellow
WJ
William Jarnagin
44 papers
Kate Kelley
39 papers
MD
Michael D'Angelica
33 papers
ML
Maeve Lowery
32 papers · 16 as a resident
ID
Imane El Dika
30 papers · 29 as a resident
JS
Jinru Shia
22 papers
LS
Leonard Saltz
22 papers
AW
Alice Wei
21 papers
AC
Andrea Cercek
21 papers
Anthony El-Khoueiry
21 papers

Clinical trials

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Principal investigator · Recruiting · Phase 3
J-Pharma Co., Ltd.
2026–2027
Registry to Collect Health Information Related to Fibrolamellar Cancer
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2021–2025
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Principal investigator · Completed · Phase 1
Polaris Group
2014–2016
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2013–2027